ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

November 10, 2017
ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics' CRISPR/Cas9 genome editing intellectual property f...

Advertisement

Recent related news

BOSTON--(BUSINESS WIRE)--Cerveau Technologies Inc and Enigma Biomedical Group, Inc., today announced an agreement with the Centre for Addiction and Mental Health...
4 days ago • Business Wire
DUBLIN--(BUSINESS WIRE)--ERS Genomics announced today that The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier...
2 days ago • Business Wire
VANCOUVER, British Columbia, Nov. 22, 2017 (GLOBE NEWSWIRE) -- *Isodiol International Inc.* (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)* (the “Company” or...
2 days ago • GlobeNewswire
LAS VEGAS, NV--(Marketwired - Nov 16, 2017) - Skinvisible Pharmaceuticals, Inc. ("Skinvisible") (OTCQB: SKVI), a research and development company with a patented...
1 week ago • Marketwired
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively...
1 week ago • Business Wire
CALGARY, Alberta, Nov. 23, 2017 (GLOBE NEWSWIRE) -- *New West Energy Services Inc.* (TSX Venture:NWE), an oil and gas and environmental services company focused...
23 hours ago • GlobeNewswire

You might like